Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2021-07-14 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于第一期员工持股计划第一个锁定期届满的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from Shenzhen BGI Genomics Co., Ltd. regarding the expiration of the first lock-up period of its first employee stock ownership plan. It details the stock holding situation, lock-up period expiration, subsequent arrangements, and the plan's duration, changes, and termination conditions. The document is an announcement about the status and updates of an employee stock ownership plan, not a financial report, earnings release, or regulatory filing. It does not contain financial statements or detailed financial data but rather informs shareholders and the public about the employee stock plan's lock-up period expiration and related matters. This fits best under the category of Capital/Financing Update (CAP), as it relates to employee stock ownership plans and shareholding changes within the company.
2021-07-14 Chinese
关于控股子公司产品获得欧盟CE准入资质的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shenzhen BGI Genomics Co., Ltd. regarding its controlling subsidiary's products obtaining EU CE certification. It details the product information, market context, and potential impact on the company. The document is short (1346 characters) and serves as an official announcement of a regulatory milestone rather than a financial report or detailed management discussion. There is no financial data, no mention of annual or quarterly results, no voting results, no management changes, or other report types. It is a regulatory announcement about product certification and market qualification. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-07-12 Chinese
关于股东减持计划时间过半的进展公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the progress of a shareholder's planned reduction in shareholding, specifically stating that the shareholder has not reduced shares during the first half of the planned period. It references regulatory compliance and disclosure obligations related to shareholding changes. The content focuses on shareholder share reduction plans and progress, not on financial results, management changes, or other report types. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes or planned changes in significant share ownership levels.
2021-07-09 Chinese
关于重大经营合同的进展公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the progress of a significant business contract involving the company's wholly-owned subsidiary and a foreign entity. It provides updates on contract extensions, additional contract amounts, and the impact on the company's operations and financials. The document is relatively short (2201 characters) and focuses on contract progress rather than detailed financial statements or comprehensive report content. It does not contain financial statements or detailed financial analysis, nor is it a transcript, management report, or regulatory certification. It is a specific update on a material contract, which fits best under the category of Regulatory Filings (RNS) as it is a general regulatory announcement about a material contract progress and risk disclosure, not a full financial report or other specialized filing type.
2021-07-05 Chinese
关于受让控股子公司少数股东股权进展暨北京医检完成工商变更登记的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of a transaction where the company Shenzhen Huada Gene Co., Ltd. acquired minority equity interests in its subsidiaries, making them wholly owned. It details the transaction overview, progress, and completion of business registration changes. The document is relatively short (1797 characters) and focuses on corporate transaction updates rather than financial results or detailed reports. It does not contain financial statements or detailed financial analysis. It is not a full report like an Annual Report or Interim Report, nor is it a call transcript or earnings release. It is a regulatory announcement about a capital transaction and corporate structure change. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-07-02 Chinese
深圳华大基因股份有限公司公司债券临时受托管理事务报告
Regulatory Filings
2021-06-30 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.